UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?

Pakozdi, A; Wilson, H; Black, CM; Denton, CP; (2009) Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis? Clin Exp Rheumatol , 27 (3 Suppl ) pp. 5-8.

Full text not available from this repository.

Abstract

OBJECTIVES: Oesophageal scintigraphy is an effective, non-invasive screening test to detect oesophageal dysmotility and reflux. Our objective was to assess the long term effect of lansoprazole therapy on gastroesophageal dysmotility in systemic sclerosis (SSc). METHODS: 24 SSc patients were randomised to receive either lansoprazole 30 mg or placebo for 12 months. Gastroesophageal motility was assessed by scintigraphy at baseline, after 6 months and after 12 months. Symptoms were evaluated by self-reported gastrointestinal questionnaire. RESULTS: Of 21 patients starting treatment, 17 (81%) completed the first 6 months and 13 (62%) completed the study. 3 patients from each group were withdrawn due to adverse events. As expected, lansoprazole appeared to decrease frequency of gastroesophageal symptoms in the first 6 months of treatment, but long term benefit was not evident. Scintigraphy showed worsening oesophageal dysmotility in SSc patients irrespective of lansoprazole treatment. In addition, early signs of dysmotility were found in asymptomatic patients. We found no correlation of scintigraphy findings with symptoms of gastroesophageal dysmotility. CONCLUSION: Although lansoprazole 30 mg daily appears to suppress SSc-related gastroesophageal symptoms in the short term, benefit was not sustained at 12 months, and there was no evidence that progression of gastroesophageal motility was prevented. Scintigraphy findings did not correlate with symptoms of dysphagia.

Type: Article
Title: Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?
Location: Italy
Keywords: 2-Pyridinylmethylsulfinylbenzimidazoles, Adult, Aged, Anti-Ulcer Agents, Disease Progression, Esophagus, Female, Gastroesophageal Reflux, Gastrointestinal Motility, Humans, Lansoprazole, Male, Middle Aged, Prospective Studies, Proton Pump Inhibitors, Radionuclide Imaging, Scleroderma, Systemic, Surveys and Questionnaires, Treatment Outcome
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: http://discovery.ucl.ac.uk/id/eprint/738407
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item